A Dose Ranging Study To Investigate The Efficacy And Safety Of SB-742457 In Alzheimer's Disease
NCT ID: NCT00224497
Last Updated: 2009-12-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
380 participants
INTERVENTIONAL
2005-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SB-742457
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects and their caregivers must provide informed consent prior to study entry.
* Adequate blood pressure and laboratory values.
Exclusion Criteria
* Have other causes of dementia such as vascular damage, depression, bipolar affective disorder, schizophrenia, syphilis, vitamin B12 deficiency or thyroid deficiency.
* Subjects taking medication for Alzheimer's disease or centrally acting agents which might impact study outcomes.
* Subjects taking agents for which there is a theoretical risk of interaction with SB-742457.
* Subjects with known hypersensitivity to sunlight or seizures.
50 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
GSK
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials, MD
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Hall in Tirol, , Austria
GSK Investigational Site
Innsbruck, , Austria
GSK Investigational Site
Retz, , Austria
GSK Investigational Site
Vienna, , Austria
GSK Investigational Site
Vienna, , Austria
GSK Investigational Site
Plovdiv, , Bulgaria
GSK Investigational Site
Sofia, , Bulgaria
GSK Investigational Site
Sofia, , Bulgaria
GSK Investigational Site
Sofia, , Bulgaria
GSK Investigational Site
Varna, , Bulgaria
GSK Investigational Site
Valparaíso, Región de Valparaíso, Chile
GSK Investigational Site
Providencia / Santiago, Región Metro de Santiago, Chile
GSK Investigational Site
Santiago, Región Metro de Santiago, Chile
GSK Investigational Site
Split, , Croatia
GSK Investigational Site
Zagreb, , Croatia
GSK Investigational Site
Olomouc, , Czechia
GSK Investigational Site
Ostrava, , Czechia
GSK Investigational Site
Prague, , Czechia
GSK Investigational Site
Rychnov nad Kněžnou, , Czechia
GSK Investigational Site
Athens, , Greece
GSK Investigational Site
Athens, , Greece
GSK Investigational Site
Melíssia, , Greece
GSK Investigational Site
Thessaloniki, , Greece
GSK Investigational Site
Auckland, , New Zealand
GSK Investigational Site
Christchurch, , New Zealand
GSK Investigational Site
Mosina, , Poland
GSK Investigational Site
Olsztyn, , Poland
GSK Investigational Site
Warsaw, , Poland
GSK Investigational Site
Moscow, , Russia
GSK Investigational Site
Moscow, , Russia
GSK Investigational Site
Saint Petersburg, , Russia
GSK Investigational Site
Bratislava, , Slovakia
GSK Investigational Site
Bratislava, , Slovakia
GSK Investigational Site
Bratislava, , Slovakia
GSK Investigational Site
Bratislava, , Slovakia
GSK Investigational Site
Košice, , Slovakia
GSK Investigational Site
Rimavská Sobota, , Slovakia
GSK Investigational Site
Oakdale, , South Africa
GSK Investigational Site
Rosebank, , South Africa
GSK Investigational Site
Somerset West, , South Africa
GSK Investigational Site
Seoul, , South Korea
GSK Investigational Site
Seoul, , South Korea
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Sant Cugat Del Vallés/, , Spain
GSK Investigational Site
Tarrasa, Barcelona, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AZ3100603
Identifier Type: -
Identifier Source: org_study_id